Genprex (NASDAQ: GNPX), a clinical-stage gene therapy
company developing potentially life-changing technologies for patients with
cancer and other serious diseases, on Wednesday announced that it has entered
into securities purchase agreements with institutional investors for the
purchase and sale of 5,000,000 shares of common stock, par value $0.001 per
share, at an offering price of $3.50 each, pursuant to a registered direct
offering, priced at-the-market under Nasdaq rules. There are no warrants in the
offering. The company intends to use the proceeds from the offering, which are
anticipated to be roughly $17,500,000 before deducting fees and other estimated
offering expenses, towards the advancement of its lead clinical programs in
non-small cell lung cancer (“NSCLC”) and for working capital and general
corporate purposes. A.G.P./Alliance Global Partners is acting as lead placement
agent, and Joseph Gunnar & Co., LLC is acting as co-placement agent for the
offering. Subject to the satisfaction of customary closing conditions, the
registered direct offering is expected to close on or about February 21, 2020.
To view the full press release, visit http://ibn.fm/kLPkD
About Genprex, Inc.
Genprex, Inc. is a clinical-stage gene therapy company
developing potentially life-changing technologies for patients with cancer and
other serious diseases. Genprex’s technologies are designed to administer
disease-fighting genes to provide new treatment options for large patient
populations with cancer and other serious diseases who currently have limited
treatment options. Genprex works with world-class institutions and
collaborators to in-license and develop drug candidates to further its pipeline
of gene therapies in order to provide novel treatment approaches for patients
with cancer and other serious diseases. The company’s lead product candidate,
Oncoprex(TM) immunogene therapy for non-small cell lung cancer (“NSCLC”), uses
the company’s unique, proprietary platform which delivers cancer-fighting genes
by encapsulating them into nanoscale hollow spheres called nanovesicles, which
are then administered intravenously and taken up by tumor cells where they
express proteins that are missing or found in low quantities. In January 2020,
the FDA granted Fast Track Designation for Oncoprex in combination with
AstraZeneca’s Tagrisso(R) for the treatment of NSCLC. For more information,
please visit the company’s website at www.Genprex.com.
NOTE TO INVESTORS: The latest news and updates
relating to GNPX are available in the company’s newsroom at http://ibn.fm/GNPX
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news breaks
keep you up-to-date with the day’s top movers. MissionIR is primarily focused
on strategic communications. We have executed countless communications programs
to address the needs of companies ranging from start-ups to established
industry leaders, gaining valuable experience and the expertise necessary to
determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
